Volume 5, Issue 2, March 2020, Page: 55-62
Xanthine Oxidase Activity in Patients with Sickle Cell Anaemia Presenting with Vaso-Occlusive Crises in University College Hospital, Ibadan
Odebiyi Ha, Department of Haematology, University College Hospital, Ibadan, Nigeria
Fasola Fa, Department of Haematology, University College Hospital, Ibadan, Nigeria; Department of Haematology, Faculty of Basic Medical Sciences, College of Medicine, University of Ibadan, University College Hospital, Ibadan, Nigeria
Received: Jun. 2, 2020;       Accepted: Jun. 19, 2020;       Published: Jul. 4, 2020
DOI: 10.11648/j.ajlm.20200502.13      View  86      Downloads  24
Abstract
Recurrent bone pain or vaso-occlusive crisis (VOC) constitutes a major presentation in patients with sickle cell anaemia. This is partly attributable to vasospasm, oxidative stress and inflammation. Xanthine oxidase is released during VOC and it had been implicated in the pathogenesis of bone pain crisis in patients with sickle cell anaemia. This study was aimed at comparing the plasma levels of xanthine oxidase activity in adult patients with Sickle cell anaemia (SCA), during bone pain crisis (BPC) and steady state and correlating it with the severity of bone pain crisis. Thirty adult sickle cell anemia patients with BPC and 30 in steady state attending Haematology clinic at the University College Hospital, Ibadan, Nigeria and 30 normal haemoglobin A, age- and sex-matched controls were enrolled for this study. Severity of BPC was assessed with total summary pain score. Haematological parameters were determined by a 5-part autoanalyzer. Plasma xanthine oxidase activity was determined using enzyme linked immunosorbent assay (ELISA). Data obtained were analyzed using the Statistical Package for the Social Science (SPSS) version 20. Results were considered statistically significant if p<0.05. Biochemical parameters were correlated with the severity of bone pain crisis. Plasma xanthine oxidase activity was significantly elevated in the BPC group than in the steady state group (p=0.000) and HbA group (p=0.000). There steady state group plasma xanthine oxidase activity was also significantly higher than that of HbA group (p-0.032). Similarly, the plasma Plasma xanthine oxidase activity was significantly higher in all BPC severity group than steady state group with associated significantly low positive correlation of xanthine oxidase activity and bone pain severity. This study established that plasma xanthine oxidase activity was higher in patients with SCA presenting in bone pain crisis than steady state and HbA individual with associated positive correlation between plasma xanthine oxidase activity and bone pain severity.
Keywords
Sickle Cell Anaemia, Plasma Xanthine Oxidase Activity, Bone Pain Crisis, Steady State, HbA
To cite this article
Odebiyi Ha, Fasola Fa, Xanthine Oxidase Activity in Patients with Sickle Cell Anaemia Presenting with Vaso-Occlusive Crises in University College Hospital, Ibadan, American Journal of Laboratory Medicine. Vol. 5, No. 2, 2020, pp. 55-62. doi: 10.11648/j.ajlm.20200502.13
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Adekile A. What’s new in the pathophysiology of sickle cell disease? Med Princ Pr. 2013; 22 (4): 311–2.
[2]
Darbari DS, Wang Z, Kwak M, Hildesheim M, Nichols J, Allen D, et al. Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study. PLoS One [Internet]. 2013 Nov 5; 8 (11): e79923–e79923. Available from: https://pubmed.ncbi.nlm.nih.gov/24224021.
[3]
Adekunle EA, Olaniyi JA OW. Adult Sickle Cell Anaemia Patients in Bone Pain Crisis have elevated Pro-Inflammatory Cytokines. Mediterr J Hematol Infect Dis. 2018; 10 (1): 1–9.
[4]
Aslan M, Ryan T, Adler B, Townes T, Parks D, Thompson J, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci U S A. 2001; 98 (26): 15215–20.
[5]
Stark K, Seubert P, Lynch G, Baudry M. Proteolytic conversion of xanthine dehydrogenase to xanthine oxidase: evidence against a role for calcium-activated protease (calpain). Biochem Biophys Res Commun [Internet]. 1989 Dec 15; 165 (2): 858–64. Available from: https://pubmed.ncbi.nlm.nih.gov/2557023.
[6]
Pal P, Alex N, Csaba S. Therapeutic Effect of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol. Pharmacol Rev. 2006; 58 (1): 87–114.
[7]
Carcao M, Dawn C, Uptom A, Jeremy F, Nadya C. Acute Painful episodes vaso-occlusive Crisis: Guidelines for management in Children with Sickle cell disease. Clin Pract Guidel. 2016; 5: 1–9.
[8]
Ramos C, Pou S, Britigan B, Cohen M, Rosen G. Spin trapping evidence for myeloperoxidase-dependent hydroxyl radical formation by human neutrophils and monocytes. J Biol Chem. 1992; 267: 8307–8312.
[9]
Contributors W. Xanthine oxidase [Internet]. Wikipedia, The Free Encyclopedia. 2019 [cited 2020 Feb 8]. p. Xanthine oxidase. Available from: https://en.wikipedia.org/w/index.php?title=Xanthine_oxidase&oldid=930242442.
[10]
Nagabudu E, Fabry ME, Nagel RL and RM. heme degradation and oxidative stress in murine model of hemoglobinopathies. Blood cells Mol Dis. 2008; 41: 61–6.
[11]
Sheng K, Shariff M, Hebbel RP. Comparative Oxidation of Hemoglobins A and S. Blood [Internet]. 1998; 91 (9): 3467–70. Available from: http://bloodjournal.hematologylibrary.org/content/91/9/3467.abstract.
[12]
Battelli MG, Polito L, Bortolotti M, Bolognesi A. Xanthine Oxidoreductase-Derived Reactive Species: Physiological and Pathological Effects. Reed TT, editor. Oxid Med Cell Longev [Internet]. 2016; 2016: 3527579. Available from: https://doi.org/10.1155/2016/3527579.
[13]
Morris, C, Suh, J, Hagar, W, Larkin S BD. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood. 2008; 111: 402–410.
[14]
Perricone AJ, Vander Heide RS. Novel therapeutic strategies for ischemic heart disease. Pharmacol Res [Internet]. 2014; 89: 36–45. Available from: http://dx.doi.org/10.1016/j.phrs.2014.08.004.
[15]
Aslan M, Thornley-Brown D, Freeman B a. Reactive species in sickle cell disease. Ann N Y Acad Sci. 2000; 899: 375–91.
[16]
Chirico EN, Pialoux V, Lyon D, Lyon CB. Critical Review Role of Oxidative Stress in the Pathogenesis of Sickle Cell Disease. 2012; 64 (January): 72–80.
[17]
Fasola F, Adedapo K, Anetor J, Kuti M. Total antioxidants status and some hematological values in sickle cell disease patients in steady state. J Natl Med Assoc. 2007; 99 (8): 891–4.
[18]
Osarogiagbon U, Choong S. Reperfusion injury Reperfusion injury pathophysiology in sickle transgenic mice. Blood. 2000; 96: 314–20.
[19]
Gardner R V. Sickle Cell Disease: Advances in Treatment. Ochsner J [Internet]. 2018; 18 (4): 377–89. Available from: https: //pubmed.ncbi.nlm.nih.gov/30559624.
[20]
Torres L CN. Emerging pharmacotherapeutic approaches for the management of sickle cell disease. Expert Opin. Pharmacother. 2018; 20 (2): 173–86.
[21]
White C, Darley-Usmar V, Berrington W, McAdams M, Gore J, Thompson J, et al. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci U S A. 1996; 93 (16): 8745–9.
[22]
Platt O. Pain in Sickle Cell disease. N Engl J Med. 1991; 325 (1): Platt, O. S., et al., Pain in Sickle Cell Disease.
[23]
Adekunle E, Olaniyi J, Oladapo W. Adult Sickle CellAnaemia Patients in Bone Pain Crisis have elevated Pro-Inflammatory Cytokines. Mediterr J Hematol Infect Dis. 2018; 10 (1): 1–9.
[24]
Hassoun F, Shedd J, Zulueta V. Regulation of endothelial cell xanthine dehydrogenase and xanthine oxidase gene expression by oxygen tension. Am J Physiol. 2004; 10: 163–71.
[25]
Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal [Internet]. 2013/10/22. 2014 Mar 1; 20 (7): 1126–67. Available from: https://pubmed.ncbi.nlm.nih.gov/23991888.
[26]
Battelli M. et al. Pathophysiology of circulating xanthine oxidoreductase: New emergingroles for a multi-tasking enzyme /. Biochim Biophys Acta. 2014; 18 (42): 1502–1517.
[27]
Linder N, Martelin M, Lapatto R, Raivio K. Posttranslational inactivation of human xanthine oxidoreductase by oxygen under standard cell culture conditions. Am J Physiol Cell Physiol. 2003; 285 (1): 48–55.
[28]
Kelley E et al. Moderate hypoxia induces xanthine oxidoreductase activity in arterial endothelial cells. Free Radic Biol Med. 2006; 40 (6): 952–9.
[29]
Hughes AK, Stricklett PK, Padilla E, Kohan DE. Effect of reactive oxygen species on endothelin-1 production by human mesangial cells. Kidney Int. 1996 Jan; 49 (1): 181–9.
[30]
Lee C Il, Liu X, Zweier JL. Regulation of xanthine oxidase by nitric oxide and peroxynitrite. J Biol Chem. 2000; 275 (13): 9369–76.
[31]
Herken H, Gurel A, Selek S, Armutcu F, Ozen ME, Bulut M, et al. Adenosine Deaminase, Nitric Oxide, Superoxide Dismutase, and Xanthine Oxidase in Patients with Major Depression: Impact of Antidepressant Treatment. Arch Med Res. 2007; 38 (2): 247–52.
Browse journals by subject